[Combined treatment for pain from bone metastases in patients with prostate cancer].
OBJECTIVE
To evaluate the effects of combined treatment of hormone therapy with strontium-89 for pain from bone metastases in patients with prostate cancer.


METHODS
Sixteen patients with metastasis prostate cancer received hormone therapy with strontium-89 chloride (89Sr), and 4 of them received radiotherapy.


RESULTS
The pain was relieved. Relief occurred in 75.6% of the patients for 3 months, 80.5% for 6 months and 63.4% for 9 months.


CONCLUSIONS
Hormone therapy enhances the effect of 89Sr without obvious toxicity. The combined treatment not only significantly raises pain palliation, prolongs pain-free survival, but improves the patients life quality.
Ren
Xiaomin
X
Department of Urology, Shanghai Ninth People's Hospital Affiliated to Shanghai Second Medical University, Shanghai 200011, China. renxmb@online.sb.cn
Ying
Jun
J
Yao
Dehong
D
Ye
Chuanyang
C
Jiang
Yueqing
Y
D000368:Aged; D000369:Aged, 80 and over; D000726:Androgen Antagonists / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000503:physiopathology* / Q000556:secondary* / Q000628:therapy; D003131:Combined Modality Therapy; D006801:Humans; D008297:Male; D008875:Middle Aged; D010148:Intractable Pain / Q000628:therapy*; D011471:Prostatic Neoplasms / Q000628:therapy*; D013324:Strontium / Q000627:therapeutic use
D000726:Androgen Antagonists; C025700:strontium chloride; D013324:Strontium